CN104684549A - 治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合 - Google Patents

治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合 Download PDF

Info

Publication number
CN104684549A
CN104684549A CN201380019041.9A CN201380019041A CN104684549A CN 104684549 A CN104684549 A CN 104684549A CN 201380019041 A CN201380019041 A CN 201380019041A CN 104684549 A CN104684549 A CN 104684549A
Authority
CN
China
Prior art keywords
officinal salt
effective dose
treatment
acceptable solvent
acceptable solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380019041.9A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·卡尔塔比亚诺
埃利奥特·奥尔施泰因
斯图尔特·麦卡勒姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velicept Therapeutics Inc
Original Assignee
AltheRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AltheRx Inc filed Critical AltheRx Inc
Publication of CN104684549A publication Critical patent/CN104684549A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380019041.9A 2012-02-09 2013-02-08 治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合 Pending CN104684549A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
US61/596,893 2012-02-09
PCT/US2013/025285 WO2013119910A1 (fr) 2012-02-09 2013-02-08 Combinaison d'antagonistes des récepteurs muscariniques et d'agonistes de l'adrénorécepteur bêta -3 pour le traitement de la vessie hyperactive

Publications (1)

Publication Number Publication Date
CN104684549A true CN104684549A (zh) 2015-06-03

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380019041.9A Pending CN104684549A (zh) 2012-02-09 2013-02-08 治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合

Country Status (13)

Country Link
EP (1) EP2811989A1 (fr)
JP (1) JP2015509931A (fr)
KR (1) KR20150020160A (fr)
CN (1) CN104684549A (fr)
AR (1) AR089957A1 (fr)
AU (1) AU2013216864A1 (fr)
CA (1) CA2864173A1 (fr)
HK (1) HK1204966A1 (fr)
IL (1) IL234033A0 (fr)
PH (1) PH12014501814A1 (fr)
SG (1) SG11201404776PA (fr)
TW (1) TW201338772A (fr)
WO (1) WO2013119910A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041806A2 (fr) * 2002-10-30 2004-05-21 Theravance, Inc. 4-amino-1-(pyridylmethyl) piperidine substituee et composes associes
WO2004047838A2 (fr) * 2002-11-27 2004-06-10 Boehringer Ingelheim International Gmbh Composition pharmaceutique a base d'agonistes des recepteurs beta-3-adrenergiques et d'antimuscariniques
WO2011043942A1 (fr) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Polythérapie utilisant un agoniste des récepteurs adrénergiques bêta-3 et un agent antimuscarinique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (fr) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
WO2008121268A1 (fr) * 2007-03-29 2008-10-09 Merck & Co., Inc. Polythérapie pour le traitement de troubles urinaires du bas appareil
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
WO2011025690A1 (fr) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Nouveaux agonistes de récepteurs adrénergiques bêta 3 dérivés de pyrrolidine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041806A2 (fr) * 2002-10-30 2004-05-21 Theravance, Inc. 4-amino-1-(pyridylmethyl) piperidine substituee et composes associes
WO2004047838A2 (fr) * 2002-11-27 2004-06-10 Boehringer Ingelheim International Gmbh Composition pharmaceutique a base d'agonistes des recepteurs beta-3-adrenergiques et d'antimuscariniques
WO2011043942A1 (fr) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Polythérapie utilisant un agoniste des récepteurs adrénergiques bêta-3 et un agent antimuscarinique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEXANDRA HICKS, ET. AL.: "GW427353 (Solabegron), a Novel, Selective β3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog", 《THE JOURNAL OF PHARMACOLOGY ANDEXPERIMENTAL THERAPEUTICS》, vol. 323, no. 1, 31 December 2007 (2007-12-31), pages 202 - 209, XP002658787, DOI: doi:10.1124/JPET.107.125757 *

Also Published As

Publication number Publication date
HK1204966A1 (en) 2015-12-11
AU2013216864A1 (en) 2014-09-11
AR089957A1 (es) 2014-10-01
KR20150020160A (ko) 2015-02-25
WO2013119910A1 (fr) 2013-08-15
JP2015509931A (ja) 2015-04-02
EP2811989A1 (fr) 2014-12-17
TW201338772A (zh) 2013-10-01
CA2864173A1 (fr) 2013-08-15
PH12014501814A1 (en) 2014-11-24
IL234033A0 (en) 2014-09-30
SG11201404776PA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
JP6441267B2 (ja) 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
US9522129B2 (en) Pharmaceutical Combination
CN105520924B (zh) 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和抗癫痫药的联合药物
CN104684549A (zh) 治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合
US10668034B2 (en) Pharmaceutical compositions and the treatment of overactive bladder
JP2000515525A (ja) 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
JP2010514696A (ja) 心血管症状の低減
WO2016004056A1 (fr) Combinaisons pharmaceutiques
CN1543344A (zh) 治疗尿失禁的芳基(或杂芳基)氮杂茂甲醇衍生物
US20110021542A1 (en) Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder
TW383222B (en) Pharmaceutical composition of bicycloheptane derivatives
Michel A benefit-risk assessment of extended-release oxybutynin
JPWO2005007155A1 (ja) 医薬組成物
JP2000159689A (ja) 月経異常の処置又は予防剤
CA2497464A1 (fr) Agent therapeutique pour soulager les douleurs perineales et/ou hypogastriques

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150603

WD01 Invention patent application deemed withdrawn after publication